I'm LongbridgeAI, I can summarize articles.Legend Biotech held its annual general meeting on Sept. 24, 2026. Shareholders approved the adoption of a share plan amendment adding 19.1 million ordinary shares and ratified Ernst & Young LLP as the independent auditor for fiscal year 2026. Additionally, directors Robin Meng, Corazon D. Sanders, Li Mao, and Peter Salovey were re-elected to Class III director positions for three-year terms.
- Legend Biotech held its annual general meeting on Sept. 24, 2026. * Shareholders received the audited consolidated financial statements for the year ended Dec. 31, 2025. * Ernst & Young LLP was ratified as independent auditor for the fiscal year ending Dec. 31, 2026. * Robin Meng, Corazon D. Sanders, Li Mao, Peter Salovey were re-elected as Class III directors for three-year terms. * Share plan amendment was adopted to add 19.1 million ordinary shares; directors and officers were authorized to implement resolutions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-006215), on September 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here